Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H11I3N2O4 |
Molecular Weight | 627.9402 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)NCC1=C(I)C(C(O)=O)=C(I)C(NC(C)=O)=C1I
InChI
InChIKey=VVDGWALACJEJKG-UHFFFAOYSA-N
InChI=1S/C12H11I3N2O4/c1-4(18)16-3-6-8(13)7(12(20)21)10(15)11(9(6)14)17-5(2)19/h3H2,1-2H3,(H,16,18)(H,17,19)(H,20,21)
Molecular Formula | C12H11I3N2O4 |
Molecular Weight | 627.9402 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: http://www.drugfuture.com/mt/meglumine-iodamide.pdf
Sources: http://www.drugfuture.com/mt/meglumine-iodamide.pdf
Iodamide is an ionic monomeric iodinated radiographic contrast medium. It was used in many procedures and may be given intravenously or by other routes, for example by instillation into the bladder or uterus; it has also been used for computed tomography. It is usually given as a 24 to 65% solution of the meglumine salt, or as a mixture of the sodium and meglumine salts; solutions of the sodium salt have also been used. Iodamide is no longer marketed in the US.
Originator
Sources: http://corporate.bracco.com/gb-en/history
Curator's Comment: In 1962 Bracco researchers develop the first original contrast agent from their in-house research, with reduced toxicity and high tolerability: iodamide.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: https://www.ndrugs.com/?s=renovue-65 |
Diagnostic | RENOVUE-65 Approved UseUnknown Launch Date1978 |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.02 g × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/338644 |
9.8 g single, intravenous dose: 9.8 g route of administration: Intravenous experiment type: SINGLE co-administered: |
IODAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
2.58 g × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/338644 |
24.75 g single, intravenous dose: 24.75 g route of administration: Intravenous experiment type: SINGLE co-administered: |
IODAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
6.69 g × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/338644 |
61.82 g single, intravenous dose: 61.82 g route of administration: Intravenous experiment type: SINGLE co-administered: |
IODAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/338644 |
9.8 g single, intravenous dose: 9.8 g route of administration: Intravenous experiment type: SINGLE co-administered: |
IODAMIDE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
1.29 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/338644 |
24.75 g single, intravenous dose: 24.75 g route of administration: Intravenous experiment type: SINGLE co-administered: |
IODAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1.02 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/338644 |
61.82 g single, intravenous dose: 61.82 g route of administration: Intravenous experiment type: SINGLE co-administered: |
IODAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
95% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/338644 |
24.75 g single, intravenous dose: 24.75 g route of administration: Intravenous experiment type: SINGLE co-administered: |
IODAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
95% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/338644 |
61.82 g single, intravenous dose: 61.82 g route of administration: Intravenous experiment type: SINGLE co-administered: |
IODAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Comparative multiclinical studies of iodamide and diatrizoate in excretory urography. | 1973 Jan |
|
[The effect of diagnostic contrast media on the activity of lactate dehydrogenase in rat blood]. | 2002 Jul-Aug |
|
Contrast-enhanced voiding US for grading of reflux in adult patients prior to antireflux ureteral implantation. | 2004 Oct |
|
Effects of iodinated contrast media on endothelium: An in vitro study. | 2007 Mar |
|
Diagnostic image quality of hysterosalpingography: ionic versus non ionic water soluble iodinated contrast media. | 2009 Jul |
Sample Use Guides
In Vivo Use Guide
Sources: http://www.drugfuture.com/mt/meglumine-iodamide.pdf
24% or 65%
Route of Administration:
Intravenous
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 16:31:38 GMT 2023
by
admin
on
Sat Dec 16 16:31:38 GMT 2023
|
Record UNII |
4RII332O0R
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C28500
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
||
|
WHO-ATC |
V08AA03
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
||
|
WHO-VATC |
QV08AA03
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DB08948
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | |||
|
m6325
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | Merck Index | ||
|
IODAMIDE
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | |||
|
DTXSID1023150
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | |||
|
1922
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | |||
|
31703
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | |||
|
5928
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | RxNorm | ||
|
CHEMBL1201239
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | |||
|
3723
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | |||
|
C65928
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | |||
|
D007451
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | |||
|
4RII332O0R
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | |||
|
1452
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | |||
|
SUB08210MIG
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | |||
|
100000083424
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | |||
|
207-125-1
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY | |||
|
440-58-4
Created by
admin on Sat Dec 16 16:31:39 GMT 2023 , Edited by admin on Sat Dec 16 16:31:39 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |